Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bioton buys BioPartners
April 2007
SHARING OPTIONS:

BAAR, SwitzerlandóBiopartners Holdings AG announced that it was purchased in a deal worth $78 million by Bioton S.A., a Polish biotechnology company. Bioton S.A. and entities associated with DLJ Merchant Banking Partners signed a purchase agreement for 100 percent of the shares in share capital on March 9, 2007, including the subsidiaries Biopartners GmbH of Switzerland and Biopartners GmbH of Germany.
 
Biopartners' main products include Valtropin, slow release human growth hormone, Interferon beta, Alpheon and Ravanex. The terms of the agreement reportedly ensure that all Biopartners' operations will remain untouched, with all drug development projects continuing as before under the same management.
 
Jean-NoŽl Treilles, CEO of Biopartners says, "Bioton S.A. and Biopartners Holdings AG are complementary companies with excellent synergies in production and marketing, as well as sales and distribution. This acquisition will bring together each company's unique expertise, enabling expansion and acceleration of product development reducing a product's 'time-to-market.'"
 
Bioton S.A. products include recombinant human insulin and its pharmaceutical forms, as well as preparations from the cephalosporine, aminoglycoside and macrolide groups.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.